Group 1 - The company announced on August 8 that it received a written resignation report from its board secretary and director, Zhu Ting, who is resigning for personal reasons [1] - Zhu Ting's resignation as board secretary is effective immediately upon delivery of the resignation report to the board [1] - After resigning from the board secretary position, Zhu Ting will continue to serve as a director of the company [1] Group 2 - To ensure the normal operation of information disclosure and other duties, the company's chairman, Liu Yang, will temporarily act as the board secretary until a new board secretary is appointed [1]

证券代码：300878 证券简称：维康药业 公告编号：2025-030 朱婷女士辞任董事会秘书职务不会影响公司正常运作，公司将按照《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关法律法规、规范性文件及《公司章程》的 规定，尽快确定董事会秘书候选人并完成董事会秘书的聘任工作。 为保证公司信息披露等工作正常进行，在新任董事会秘书到任前，暂由公司 董事长刘洋先生代行董事会秘书职责。 公司董事长刘洋先生代行董事会秘书职责期间的联系方式如下： 电话：0578-2950005 浙江维康药业股份有限公司 关于公司董事会秘书辞职暨董事长代行董事会 秘书职责的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关于董事会秘书辞职的情况 浙江维康药业股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 8 日收到公司董事会秘书、董事朱婷女士提交的书面辞职报告。朱婷女士因个人原 因，申请辞去公司董事会秘书职务。根据《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》和《公 ...

Core Viewpoint - The article highlights serious financial misconduct at Weikang Pharmaceutical, including the misuse of company funds by its actual controller, Liu Zhongliang, and the subsequent impact on the company's financial performance and project timelines [3][4][6]. Financial Misconduct - Liu Zhongliang has occupied company funds totaling 157 million yuan, including 54 million yuan of raised funds, under the guise of paying for engineering equipment [1][4]. - The funds were ultimately transferred to personal accounts controlled by Liu Zhongliang, constituting non-operational fund occupation [3][4]. - The balances of fund occupation by the actual controller from 2020 to mid-2023 were 78.12 million yuan, 89.51 million yuan, 147.28 million yuan, and 151.22 million yuan, representing 5.64%, 6.35%, 10.43%, and 10.24% of net assets respectively [3][4]. Regulatory Actions - The Zhejiang Securities Regulatory Bureau has ordered Weikang Pharmaceutical to rectify the situation, issuing a warning and imposing a fine of 5 million yuan on the company and 7 million yuan on Liu Zhongliang [4][6]. Project Delays - Weikang Pharmaceutical's initial fundraising projects have faced multiple delays, with the first phase of the health industry park originally scheduled for completion in December 2020, now pushed back multiple times to 2025 [6][7]. - The marketing center project has also seen significant delays, with no new investments reported for 2023 and 2024 [7][8]. Financial Performance - The company's financial performance has deteriorated significantly since its IPO, with net profit dropping from 96 million yuan in 2021 to a loss of 147 million yuan in 2024 [9][10]. - Revenue has also declined from 633 million yuan in 2021 to 351 million yuan in 2024, contrasting sharply with pre-IPO growth [9][10]. Dividend Payments - Despite the losses, Weikang Pharmaceutical has continued to distribute dividends, with cash dividends of 35.51 million yuan in 2023 and 19.89 million yuan in 2024, even as the actual controller holds nearly 70% of the company's shares [11].

Market Performance - The Traditional Chinese Medicine (TCM) sector rose by 0.42% on August 4, with Longshen Rongfa leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in TCM Sector - Longshen Rongfa (300534) closed at 12.09, up 7.18% with a trading volume of 646,800 shares and a turnover of 777 million yuan [1] - Weikang Pharmaceutical (300878) closed at 27.26, up 6.40% with a trading volume of 198,700 shares and a turnover of 513 million yuan [1] - Darentang (600329) closed at 41.20, up 6.30% with a trading volume of 164,600 shares and a turnover of 664 million yuan [1] Top Losers in TCM Sector - Biotech Valley (833266) closed at 12.80, down 8.51% with a trading volume of 215,700 shares and a turnover of 271 million yuan [2] - Datang Pharmaceutical (836433) closed at 8.19, down 4.88% with a trading volume of 204,800 shares and a turnover of 166 million yuan [2] - Huason Pharmaceutical (002907) closed at 20.00, down 3.57% with a trading volume of 390,300 shares and a turnover of 787 million yuan [2] Capital Flow Analysis - The TCM sector experienced a net outflow of 556 million yuan from institutional investors, while retail investors saw a net inflow of 375 million yuan [2] - The net inflow from speculative funds was 181 million yuan [2] Individual Stock Capital Flow - China Resources Sanjiu (000999) had a net inflow of 86.17 million yuan from institutional investors, while retail investors saw a net outflow of 56.84 million yuan [3] - Yabao Pharmaceutical (600351) had a net inflow of 57.28 million yuan from institutional investors, with retail investors experiencing a net outflow of 42.13 million yuan [3] - Tongrentang (600085) had a net inflow of 53.69 million yuan from institutional investors, while retail investors had a net outflow of 58.73 million yuan [3]

Report Summary 1. Report Industry Investment Rating - Not provided in the content 2. Core Viewpoints - On August 3, the four major stock index futures contracts showed mixed performance. IF fell 0.52%, IH fell 0.67%, IC fell 0.16%, and IM rose 0.21% [1]. - On this trading day, the total trading volume of stock index futures declined, indicating a cooling of investors' trading enthusiasm. The total trading volume of IF decreased by 56,758 lots, IH by 25,092 lots, IC by 30,117 lots, and IM by 54,792 lots. In terms of positions, the total positions of IF decreased by 9,118 lots, IH by 3,066 lots, IC by 6,919 lots, and IM by 10,044 lots [2]. 3. Summary by Relevant Catalogs 3.1 Index Futures Data - **Closing Prices and Fluctuations**: The closing prices and percentage changes of the four major stock indexes (CSI 300, SSE 50, CSI 500, and CSI 1000) and their corresponding futures contracts on August 3 are presented, with some rising and some falling [1]. - **Basis**: The basis of each futures contract is provided, showing the difference between the futures price and the spot price [1]. - **Trading Volume and Turnover**: The trading volume, turnover, and their changes of each futures contract are given, indicating the market activity [1]. - **Open Interest**: The open interest and its changes of each futures contract are shown, reflecting the market's holding situation [1]. 3.2 Index Futures Member Positions - The long - and short - position changes of the top 20 member institutions in each futures contract are presented, including the net changes in some contracts [5]. 3.3 Market Trends and Influencing Factors - **Trend Intensity**: The trend intensities of IF and IH are 1, and those of IC and IM are also 1, with the range of trend intensity being integers in the [-2, 2] interval [6]. - **Important Drivers**: The National Development and Reform Commission has completed the allocation of 69 billion yuan in the third batch of ultra - long - term special treasury bond funds for consumer goods trade - ins this year and will allocate the fourth batch of 69 billion yuan in October to reach the annual plan of 300 billion yuan. The NDRC will continue to promote measures to stabilize employment and the economy, and strengthen economic monitoring and policy reserve [6]. - **Other Policies**: The "Two - Key" construction project list of 800 billion yuan has been fully allocated, and the central budgetary investment of 735 billion yuan has been basically allocated. The NDRC is taking measures to address "involution - style competition" and promote the high - quality development of the private economy [7]. 3.4 Stock Market Performance - The Shanghai Composite Index fell 0.37%, the Shenzhen Component Index fell 0.17%, and the ChiNext Index fell 0.24%. The A - share trading volume was 1.62 trillion yuan, down from 1.96 trillion yuan the previous day. This week, the Shanghai Composite Index fell 0.94% and the ChiNext Index fell 0.74%. Some sectors such as innovative drugs, traditional Chinese medicine, photovoltaic industry chain, intelligent logistics, and AI agents showed strength, while AI hardware, military, stablecoin, and rare earth permanent magnet concepts declined [8].

A股中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The Chinese medicine sector saw a 3.12% increase last week, with the overall pharmaceutical sector rising by 2.95% [2] - The PE (ttm) for the Chinese medicine sector is 29.58X, up 0.89X week-on-week, while the PB (lf) is 2.45X, up 0.08X week-on-week [3] - The "Thousand-Year Herbal" initiative aims to establish a comprehensive communication system for the entire lifecycle of Chinese medicine, focusing on resource protection, quality control, and technological innovation [5] - The recent implementation of centralized procurement for Chinese medicine pieces is expected to drive industry standardization and enhance competitive advantages for companies with strong management and innovation capabilities [6] Market Performance - The Chinese medicine II index closed at 6845.97 points, reflecting a 3.12% increase, while the chemical pharmaceuticals index rose by 5.01% [2][14] - The performance of leading companies includes Qizheng Tibetan Medicine and Zhongsheng Pharmaceutical, while companies like Qidi Pharmaceutical and Kangmei Pharmaceutical lagged behind [2] Valuation - The Chinese medicine sector's PE (ttm) is at 29.58X, which is at the 35.13% percentile since 2013, while the PB (lf) is at 2.45X, at the 8.52% percentile since 2013 [3] Supply Chain Insights - The market for Chinese medicinal materials is currently balanced, with the price index remaining stable despite fluctuations in supply due to extreme weather [4] Investment Suggestions - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Companies with strong R&D capabilities and unique products are recommended, along with those less affected by centralized procurement [12]

Market Overview - The A-share market is experiencing volatility, with the Shanghai Composite Index fluctuating around 3559 points and trading volume decreasing to 1.59 trillion yuan, while northbound funds are increasing their positions in banks and photovoltaic sectors [1] - Despite a four-month contraction in manufacturing PMI, the non-manufacturing PMI remains above 50, indicating resilience in consumption and services, suggesting a mixed economic outlook [1] Policy and Funding Dynamics - The central bank is maintaining liquidity, while the Ministry of Finance has reinstated VAT on newly issued government bonds starting August 8, creating a balanced policy approach that avoids excessive capital turnover while allowing market speculation [3] - Northbound funds have shown a "seesaw" effect, with a net outflow of 25.6 billion yuan on August 1, but significant purchases in high-quality stocks like Ningbo Bank and Longi Green Energy, indicating a shift from overvalued consumer stocks to high-dividend and renewable energy sectors [3] - Margin trading balances have decreased to 1.93 trillion yuan, with leveraged funds moving away from semiconductors and telecommunications towards military and public utility sectors, suggesting a defensive positioning ahead of potential market adjustments [3] Technical Analysis and Market Signals - The Shanghai Composite Index has been oscillating between 3500 and 3600 points for nearly a month, with trading volume declining after 47 consecutive days above 1 trillion yuan, resembling a mid-marathon fatigue [4] - Key signals to monitor include northbound fund inflows exceeding 10 billion yuan for three consecutive days, trading volume returning above 1.8 trillion yuan, and July economic data, particularly social financing and PMI, exceeding expectations [4] Investment Strategy - Long-term investors are advised to allocate 60% of their portfolio to high-dividend banks and public utilities, 20% to policy-supported sectors like AI and semiconductors, and the remaining 20% to oversold consumer and pharmaceutical stocks for potential rebounds [5] - Short-term traders are cautioned against chasing stocks at their peak and are encouraged to wait for pullbacks to find better entry points [5] Sector Performance Insights - On August 1, there was a net outflow of 71.2 billion yuan from major funds, with significant sell-offs in computer and electrical equipment sectors, while AI leaders like 360 and Cambridge Technology attracted capital, indicating a shift from speculative trading to performance-based investment [6] - The current market environment suggests that companies with solid fundamentals will attract investment during the upcoming earnings disclosure period [6]